National Cancer Centre Singapore
Some information on this page may be available only to Healthcare Professionals. Please

About

Research Trials at the National Cancer Centre Singapore   

The National Cancer Centre Singapore (NCCS) is a leading national and regional tertiary cancer centre that attends to 65 per cent of all cancer cases in the public sector in Singapore. In addition to offering world class cancer care, our clinicians work closely with our scientists who conduct robust, cutting-edge clinical and translational research with local and international collaboration.  

Clinical trials are the best way to improve treatment outcomes for cancer and NCCS is leading the way with dynamic clinical trials aimed at developing novel and innovative treatments for all cancer types. With over two decades of experience, the Clinical Trials Office of the Humphrey Oei Institute of Cancer Research has conducted more than 450 phase I to III clinical trials to date and currently oversees more than 200 ongoing trials at NCCS.  

Clinical trials at NCCS are focused on evaluating the effectiveness of novel molecular targeted agents and next generation immunotherapy approaches, while implementing the use of new technologies and digital medicine tools. Biostatistical research and epidemiological surveys are also conducted to assess real-time patient experience. NCCS has multiple active bio-pharma and bio-tech collaborations for clinical and translational research, creating a pipeline to take effective treatments to market and give new hope to individuals with cancer.     

For more information, please visit: www.nccs.com.sg   

Media

YouTube Linkedin Facebook Twitter

Oncology services

General Oncology Services

  • Supportive and Palliative Care
  • Radiation Oncology
  • Oncologic Imaging
  • Psychosocial Oncology
  • Nursing
  • Surgical Oncology
  • Medical Oncology

Oncology treatment

  • Surgery
  • Local/Regional therapies
  • Immunotherapy
  • Targeted therapy
  • Chemotherapy
  • Hormonal therapy

Common tumour types seen:

All solid tumors and hematologic cancers

Specialist Services

  • Cancer Genetics
  • Comprehensive Liver Cancer
  • Cancer Education and Information Services

Branches

1

National Cancer Centre Singapore

11 Hospital Crescent, Singapore 169610

Mon—Fri: 8:30 AM — 5:30 PM

Sat: 8:30 AM — 12:30 PM

Closed on Sunday and Public Holidays

Ongoing trials at National Cancer Centre Singapore

69 trials shown

A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations

This study will assess the safety and efficacy of Osimertinib with Amivantamab as First-line Treatment in Participants with Epidermal Growth Factor Receptor Mutation-Positive, Loca

Study number:
NCT05801029
Cohorts:
1
Study phase:
2
Overall status:
Not yet recruiting
Study type:
Targeted therapy

A Study of EBC-129 in Advanced Solid Tumours

This study will assess the safety and tolerability of EBC-129 as a single agent and in combination with pembrolizumab in patients with advanced solid tumours

Study number:
NCT05701527
Cohorts:
1
Study phase:
1
Overall status:
Recruiting
Study type:
Any

A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors

To characterize safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of QEQ278 in adult patients with advanced/metastatic non-small cell lu

Study number:
NCT05462873
Cohorts:
1
Study phase:
1
Overall status:
Recruiting
Study type:
Any

Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the 7th most common cancer worldwide but is the 4th deadliest, because diagnosis tend to be late and current systemic therapies are poorly efficac

Study number:
NCT05516628
Cohorts:
1
Study phase:
2
Overall status:
Not yet recruiting
Study type:
Local/Regional therapies, Immunotherapy

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

The purpose of this study is to assess the antitumor activity, safety, and tolerability of tislelizumab plus investigational agent(s) with or without chemotherapy. This study is st

Study number:
NCT05635708
Cohorts:
2
Study phase:
2
Overall status:
Recruiting
Study type:
Any

Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole

This is a phase II study testing the combination of pembrolizumab with lenvatinib, a multi-kinase inhibitor that has activity against vascular endothelial growth factor receptors 1

Study number:
NCT05286437
Cohorts:
1
Study phase:
2
Overall status:
Recruiting
Study type:
Targeted therapy, Hormonal therapy

Phase II 177Lu-DOTATATE Study in Metastatic NPC With a Safety Run-in

This study is the first phase II study of 177Lu-DOTA0-Tyr3-Octreotate in metastatic NPC. Patients whom have failed 2 or more lines of therapy or exhausted standard therapy and are

Study number:
NCT05198479
Cohorts:
1
Study phase:
2
Overall status:
Not yet recruiting
Study type:
Any

Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients

This is a multi-national, phase II, parallel-arm, double-blind, placebo-controlled, two-arm study designed to assess the efficacy and safety of SIRT-Y90 followed by atezolizumab pl

Study number:
NCT05377034
Cohorts:
1
Study phase:
2
Overall status:
Not yet recruiting
Study type:
Local/Regional therapies, Immunotherapy, Targeted therapy

A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma

This Phase 1/ 2 study is a multicenter study to evaluate the safety, tolerability and efficacy of SCG101 in subjects with hepatitis B virus-related hepatocellular carcinoma

Study number:
NCT05417932
Cohorts:
1
Study phase:
1, 2
Overall status:
Recruiting
Study type:
Immunotherapy

Novartis

Key trial

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

This is Phase Ib/II, multicenter, open-label adaptive platform study of JDQ443 with select therapies in patients with advanced solid tumors harboring the KRAS G12C mutation.

Study number:
NCT05358249
Cohorts:
3
Study phase:
1, 2
Overall status:
Recruiting
Study type:
Targeted therapy, Biomarker